OpenEvidence announced on January 21, 2026, that it raised $250 million in Series D financing at a $12 billion private-market valuation. Thrive Capital and DST Global co-led the round. The company said the financing brought total funding to roughly $700 million and would support research, product development, computing capacity and its multi-agent architecture.
The deal nearly doubles the approximately $6 billion valuation reported for an October 2025 financing. It is a major venture bet on clinician-facing artificial intelligence—but the financing price is not audited proof of profitability, clinical benefit or a durable competitive moat.
What the financing confirms
The transaction was announced by OpenEvidence on January 21, 2026. It is a $250 million Series D led jointly by Thrive Capital and DST Global, valuing the company at $12 billion. Coverage from TechCrunch and STAT reported the same headline terms.
The available announcements do not clearly say how much of the round was new primary capital, secondary share sales or a combination. They also do not disclose profitability, gross margin, customer concentration or the price paid by each investor. The stated use of proceeds includes research, development, compute and work on a multi-agent system.
#1 Best Overall
A rapid private-market repricing
| Financing event | Reported amount | Reported valuation |
|---|---|---|
| Earlier round | $75 million | $1 billion |
| Later round | $210 million | Approximately $3.5 billion |
| October 2025 financing | Not stated in the available coverage | Approximately $6 billion |
| Series D, announced January 21, 2026 | $250 million | $12 billion |
The $75 million and $210 million figures and associated valuations come from secondary financing coverage and databases, including reported funding records. They should not be treated as a substitute for audited company financing documents. A private financing valuation is the price implied by a negotiated transaction, not a continuously traded market price.
What OpenEvidence actually does
OpenEvidence presents itself as an AI-powered medical search and clinical-information service for healthcare professionals. It synthesizes medical literature and other clinical sources into answers linked to citations. In practice, it is intended to help a physician retrieve and interpret evidence during clinical work—a “copilot” or “brain extender”—rather than an autonomous doctor.
The shorthand “ChatGPT for doctors” is incomplete. OpenEvidence is designed around medical evidence retrieval, source provenance and a physician audience, while a general chatbot is built for much broader tasks. The company’s official site provides its current product information.
The traction investors are buying
OpenEvidence’s reported growth is substantial, but the figures below are company claims rather than independently audited market-share statistics.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
| Metric | Company-reported figure | Important qualification |
|---|---|---|
| December 2025 consultations | Approximately 18 million | The term may describe platform sessions or searches, not patient encounters. |
| Monthly consultations about a year earlier | Approximately 3 million | Comparable measurement definitions are not independently established. |
| Revenue | More than $100 million | Revenue mix, recurrence and profitability were not disclosed. |
| Physician use | More than 40% of U.S. physicians use it daily on average | The denominator, survey method, specialties and time period are not specified. |
| Reach | More than 10,000 hospitals and medical centers | The announcement does not establish the nature of each organization’s use. |
“Verified healthcare professionals” does not necessarily mean independently verified clinical use, and a high consultation count does not establish better diagnoses, treatment decisions, patient outcomes or clinician productivity. Those are the tests healthcare buyers and investors will eventually need.
How the business model could work
STAT reported that eligible clinicians can use OpenEvidence without charge after verification with a national provider identifier. Free access lowers adoption friction and can accelerate word-of-mouth growth among physicians.
Potential revenue engines
- Targeted advertising: A concentrated physician audience could be valuable to pharmaceutical and medical-product companies, subject to healthcare advertising rules and disclosure requirements.
- Institutional software: Hospitals and health systems could pay for administration, security, integration, analytics or expanded workflow features.
- Premium products: Specialty tools, agentic workflows or additional controls could support paid tiers.
OpenEvidence has not publicly established that advertising is its only or dominant revenue source. Usage volume is also not the same as recurring enterprise revenue. The economic questions are how much revenue comes from each source, how stable it is and what remains after model-inference and content-licensing costs.
Why medical content may be a moat—and a burden
The company says it has official relationships involving the New England Journal of Medicine, the American Medical Association, the National Comprehensive Cancer Network and the American College of Cardiology. Licensed or otherwise authorized access to authoritative material could improve source quality and differentiate the product from systems relying primarily on broad internet data.
Free tools Windows power users keep installed
One-click scans. No signup required.
Those relationships may have different scopes—such as content access, distribution, licensing or validation—and the financing announcement does not define identical rights for each organization. Licensing can create defensibility, but it can also be a significant recurring expense and restrict margins.
Feedback from clinician use
Repeated physician queries can reveal which specialties, questions and workflows matter most. That feedback may improve retrieval and product design. It does not automatically create an uncopyable data asset: privacy controls, consent, retention policies and the handling of protected health information remain central issues.
OpenEvidence versus broader healthcare AI
| Buying question | OpenEvidence’s stated emphasis | What buyers must still verify |
|---|---|---|
| Sources | Citation-linked medical evidence and publisher relationships | Whether citations actually support each answer and how quickly guidance is updated |
| Workflow | Physician-focused point-of-care search | EHR integration, specialty coverage and response speed in real settings |
| Governance | Professional-user access controls | HIPAA safeguards, retention, audit logs, security and liability allocation |
| Economics | Free access for eligible clinicians, with other monetization possible | Enterprise pricing, advertising dependence, margins and switching costs |
OpenAI announced ChatGPT for Healthcare on January 8, 2026, and Anthropic has also pursued healthcare offerings. Large model companies bring substantial research budgets, multimodal capabilities, enterprise relationships and links to productivity software.
Established medical-reference publishers retain advantages in editorial processes, guideline depth, institutional contracts and liability practices. Electronic-health-record vendors can put evidence retrieval directly inside the clinician’s existing workflow, reducing the need for a standalone application. OpenEvidence’s response is specialization, medical-content access and physician-oriented design, but a claimed lead is not yet a demonstrated moat.
Recommended Free Tools
Best Value
- Essential guide to the language of medicine
- Includes 1 000 new words and senses
- Covers the latest brand names and generic equivalents of common drugs
- Pronunciation provided for all entries
Risks behind the $12 billion price
Clinical reliability
- A confident answer can still be wrong.
- A citation may be relevant without supporting the specific recommendation.
- Indexed evidence may be outdated when guidelines change.
- The tool may not have the patient’s complete record, allergies, medications or comorbidities.
- Overreliance could turn an aid into an unexamined authority.
Commercial and operating risk
- Pharmaceutical advertising in a clinical workflow can create perceived or actual conflicts of interest.
- Premium medical content and inference workloads may compress gross margins.
- Dependence on third-party foundation models could expose the company to pricing, availability or capability changes.
- Regulatory obligations may differ depending on whether the product retrieves information or makes treatment recommendations.
- Enterprise customers will demand detailed security, access-control and audit evidence.
What would make the valuation easier to defend?
Readers should look for operating evidence rather than relying on the financing headline alone:
- Revenue growth broken out between advertising, subscriptions and institutional contracts.
- Gross margins after compute, model and medical-content licensing costs.
- Retention and frequency of use by verified clinicians.
- The number, size and renewal rate of paying hospitals or health systems.
- Conversion of free professional users into institutional or premium revenue.
- Independent studies showing effects on clinician productivity, diagnostic accuracy, costs or patient outcomes.
- Deeper EHR integration and measurable workflow lock-in.
- Clear disclosure of data practices, liability arrangements and regulatory status.
Without audited revenue detail, it would be misleading to calculate a precise revenue multiple from the $12 billion figure. The valuation reflects investor expectations about future growth and strategic importance, not proven public-market price discovery.
What happens next
The most informative milestones will be enterprise and EHR deployments, independent clinical validation, specialty-specific or agentic product launches, international expansion and any change to free clinician access. Investors will also watch whether OpenEvidence introduces paid tiers, changes its advertising approach or discloses stronger evidence of recurring revenue and profitability.
The Bottom Line
The $250 million Series D confirms unusually strong investor confidence in OpenEvidence and nearly doubles its reported valuation to $12 billion. The company’s clinician adoption, medical-content relationships and reported revenue explain the enthusiasm, but they do not by themselves prove clinical impact, durable margins or a defensible moat. The next valuation test is whether free, high-volume physician use can become trusted, recurring and profitable healthcare infrastructure.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
